FDMT: Gene therapy platform advances with strong phase III momentum, robust safety, and commercial readiness
Revised summary: The session highlighted advances in next-gen gene therapy, with 4D-150 showing strong safety and efficacy in wet AMD and DME. Rapid enrollment and positive feedback support robust phase III trials. Commercial plans leverage a scalable field force, while financial strength and partn…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.